ERBB2 and breast carcinoma: Out of 148 breast carcinoma cases, 59 (39.4%) were classified as luminal-A, 18 (12.1%) cases as luminal-B, 59 (9.4%) as triple negative, and 12 (8.0%) as HER2(+) phenotype.